Emmanuel Macron was in Chartres this Thursday afternoon to visit the Novo Nordisk facilities. The Danish pharmaceutical giant plans to make a very significant investment there. He will inject 2.1 billion euros to double the surface area of his factory. The result is no less than 500 jobs. His goal: to be able to produce in situ his two star drugs, Ozempic (an antidiabetic) and Wegovy (used to combat heart disease and obesity).
These two treatments have propelled Novo Nordisk to the forefront. Its stock market value (422 billion euros) now exceeds that of LVMH (355 billion). It thus weighs 2.5 times more than the Swiss giant Roche (181 billion), the second European in the sector. The rise of Novo Nordisk is such that it has become the main engine of the Danish economy.
An appetite suppressant widely used for weight loss.
This group, which celebrated its centenary this year, made its first fortune with insulin, of which it remains the world’s leading producer. But if it has become the most valuable European company on the stock market, it is thanks to the meteoric growth of global sales of its two star drugs, Ozempic and Wegowy, two treatments that are based on the same molecule, semaglutide. Particularity of this active ingredient: it acts as an appetite suppressant which, combined with greater physical activity, causes weight loss.
When they went on the market, Ozempic and Wegowy were only used by those who suffered from diabetes or had cardiac risks related to being overweight, but it is their virtues as appetite suppressants that explain the meteoric growth in sales, especially in the United States. State. Companies like Novo Nordisk are struggling to meet demand. Your investment in France should help respond to this situation.
Demand should continue to grow with the likely arrival on the market of an oral version of this appetite suppressant, as Ozempic and Wegowy are prescribed in injectable versions. Last June, the group published the results of a study that showed that, after just over a year, the version taken in tablet form generated an average of 15% weight loss in obese adults. Very promising results that made the value of this pharmaceutical laboratory’s shares rise a little more.
Source: BFM TV
